Remove Antibody Remove Clinical Development Remove Life Science Remove Reagent
article thumbnail

The latest drug discovery product launches

Drug Discovery World

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos. DDW provides an update.

article thumbnail

Fortis Life Sciences leads the way in custom antibody discovery

Drug Discovery World

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows.

article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).